- Home
- MNKD vs PEB Comparison
MNKD vs PEB Comparison
Compare MNKD & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNKD
- PEB
- Stock Information
- Founded
- MNKD 1991
- PEB 2009
- Country
- MNKD United States
- PEB United States
- Employees
- MNKD N/A
- PEB N/A
- Industry
- MNKD Biotechnology: Pharmaceutical Preparations
- PEB Real Estate Investment Trusts
- Sector
- MNKD Health Care
- PEB Real Estate
- Exchange
- MNKD Nasdaq
- PEB Nasdaq
- Market Cap
- MNKD 1.1B
- PEB 1.1B
- IPO Year
- MNKD 2004
- PEB 2009
- Fundamental
- Price
- MNKD $4.06
- PEB $10.61
- Analyst Decision
- MNKD Buy
- PEB Hold
- Analyst Count
- MNKD 6
- PEB 7
- Target Price
- MNKD $9.33
- PEB $11.71
- AVG Volume (30 Days)
- MNKD 3.0M
- PEB 2.2M
- Earning Date
- MNKD 08-06-2025
- PEB 07-29-2025
- Dividend Yield
- MNKD N/A
- PEB 0.38%
- EPS Growth
- MNKD 228.27
- PEB N/A
- EPS
- MNKD 0.10
- PEB N/A
- Revenue
- MNKD $297,595,000.00
- PEB $1,459,506,000.00
- Revenue This Year
- MNKD $13.72
- PEB $1.63
- Revenue Next Year
- MNKD $14.94
- PEB $2.91
- P/E Ratio
- MNKD $39.14
- PEB N/A
- Revenue Growth
- MNKD 32.50
- PEB 2.19
- 52 Week Low
- MNKD $3.51
- PEB $7.42
- 52 Week High
- MNKD $7.63
- PEB $15.12
- Technical
- Relative Strength Index (RSI)
- MNKD 55.84
- PEB 56.13
- Support Level
- MNKD $3.74
- PEB $10.30
- Resistance Level
- MNKD $4.13
- PEB $10.87
- Average True Range (ATR)
- MNKD 0.14
- PEB 0.33
- MACD
- MNKD 0.05
- PEB -0.04
- Stochastic Oscillator
- MNKD 88.14
- PEB 32.98
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.